March 12 (Bloomberg) -- Bayer AG forecast 8 percent annual growth in pharmaceutical revenue through 2016 on demand for new medicines.
Bayer predicted 6 percent growth for its crop-science business, the company said in a statement today as executives meet with investors and analysts in Leverkusen, Germany, where the 150-year-old company is based. No specific forecast was issued for the material-science unit, which some analysts speculate may be sold or spun off.
“I’m particularly confident about our health-care business thanks to the encouraging development of the five pharmaceutical products we have recently launched,” Chief Executive Officer Marijn Dekkers said in the statement.
Bayer last month raised its forecast for peak sales of five new drugs to at least 7.5 billion euros ($10.4 billion) from more than 5.5 billion euros. The products are the blood thinner Xarelto, the Eylea eye medicine, the cancer products Stivarga and Xofigo and a treatment called Adempas for pulmonary hypertension.
Bayer fell 0.2 percent to close at 95.45 euros in Frankfurt. The stock has returned 27 percent in the year through yesterday including reinvested dividends, compared with 21 percent for the Bloomberg Europe Pharmaceutical Index. It reached a record in January.
Health-care sales will increase an average of 6 percent a year, including the 8 percent growth in drugs and a 3 percent increase in consumer health, Bayer said. Crop science aims for a profit margin of 24 percent to 25 percent, the company said.
For material science, which produces chemicals for industries including cosmetics and auto parts, the company forecast an increase in sales volume that’s greater than global economic growth, gave no prediction for profit growth and said the unit aims for a return on investment that’s greater than its cost of capital.
“Material science is having its challenges from a market point of view,” Dekkers said in his speech to analysts and investors. The company is being disciplined in its management of the unit to improve profitability, he said.
Bayer may get rid of the material science business in the next one to two years and use the proceeds to fund acquisitions in animal or consumer health, Jeffrey Holford, an analyst at Jefferies in London, said in a report last week.
Last year, Bayer’s health-care sales rose 7 percent excluding currency swings and changes in the company’s portfolio of products. Within health care, pharmaceutical sales climbed 9 percent and consumer health increased 3 percent.
Revenue for the crop-science unit that makes agricultural chemicals and seeds increased 9 percent in 2013, Bayer said Feb. 28. Sales were unchanged in the material-science unit.
FIFW NSN N1PTTW6JIJVJ <GO> Bayer to Buy Cancer-Drug Partner Algeta for $2.9 Billion (2)
FIFW NSN MY1XS86K50YL <GO> Bayer to Lanxess Plastic Creations Fail to Rescue Industry (1)
To contact the reporter on this story: Phil Serafino in Paris at firstname.lastname@example.org
To contact the editors responsible for this story: David Risser at email@example.com Robert Valpuesta, Marthe Fourcade, David Risser